NDAORALLIQUIDPriority Review
Approved
Aug 1993
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
IMAGENT (perflubron) is an oral liquid imaging agent approved in 1993 for diagnostic visualization. It is a perfluorocarbon-based contrast medium used in medical imaging applications. The drug works by providing contrast enhancement during imaging procedures.
LOE Approaching
With LOE approaching and competitive pressure at 30%, brand teams should expect rightsizing and transition focus toward legacy management or product transition strategies.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings indicate minimal active recruitment for this product team, typical of a legacy asset approaching LOE. Career growth opportunities are limited; positions on IMAGENT teams are primarily defensive, focused on protecting market share during competitive decline.
Company
Worked on IMAGENT at Alliance Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.